- About Us
- Our Story
- Our Products
- Our Science
- Our People
- Our Citizenship
-
Investors
- Reports and Filings
- Presentations
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Governance
- Investor Services
- Media
- Partners
- Canada
- Australia
- Germany
- India
- New Zealand
- China
- Netherlands
- Spain
- Contact Us
Press Releases
Oct
- Dr. Reddy's Laboratories announces new strategic deal with Gland Pharma in the U.S. Market
- Dr. Reddy’s Q2 and H1 FY17 Financial Results
- Dr. Reddy's Laboratories announces the launch of Aripiprazole tablets, USP tablets in the U.S. Market
- Leading global pharmaceutical company, Dr. Reddy’s Laboratories now in Colombia
- Dr. Reddy's Laboratories announces the launch of Lamotrigine Orally Disintegrating Tablets in the U.S. Market
Sep
- Dr. Reddy's Laboratories announces the launch of Paricalcitol Injection in the U.S. Market
- Dr. Reddy’s Expands Strategic Collaboration with Amgen in India
- Dr Reddy’s listed on Dow Jones Sustainability Indices 2016
- Dr. Reddy's Laboratories announces the launch of Bupropion HCl Extended-Release Tablets, USP (SR) in the U.S. Market
- Dr. Reddy’s announces Purple Health, a unique patient-centric platform that takes care beyond the pill
Aug
Jul
Jun
May
Mar
Feb
- Dr. Reddy’s Board approves the proposal for Buyback of its Equity Shares
- Dr. Reddy’s Q3 and 9M FY16 Financial Results
- Promius Pharma™ Receives FDA Approval for Sernivo (betamethasone dipropionate) Spray, 0.05%
- Dr. Reddy’s Laboratories Receives USFDA Tentative Approval for Zenavod™ (doxycycline) Capsules, 40 mg for the Treatment of Rosacea in Adults
